Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
about
Microtubule-binding agents: a dynamic field of cancer therapeutics.Antibody drug-conjugates targeting the tumor vasculature: Current and future developmentsNovel analogue of colchicine induces selective pro-death autophagy and necrosis in human cancer cellsImaging biomarker roadmap for cancer studiesDiscovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.Potential role of vascular targeted therapy to combat against tumor.A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumorsDCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomasCardiovascular toxicity profiles of vascular-disrupting agents.AVE8062: a new combretastatin derivative vascular disrupting agent.Combretastatin A4 phosphate: a novel vascular disrupting agent.Tumor vasculature as target for therapeutic intervention.Antiangiogenic therapies in epithelial ovarian cancer.MRI & MRS assessment of the role of the tumour microenvironment in response to therapy.Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.Recent advances in vascular disrupting agents in cancer therapy.Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis.Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions.Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent.MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation.A facile synthesis of dibenzopyrroloazepinones as tetracyclic allocolchicinoids--an unusual 1,2-phenyl shift.A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.
P2860
Q27690249-4D55C911-59D4-4284-AD00-78B519EAA2EEQ28270261-B96F18B4-B46D-4DCD-B0F4-6830CFD8AD75Q28539109-45D8F976-C0D2-493C-ABAD-339EBF1C186EQ30242020-6582A4A0-9EBF-4F79-83BF-DC264A155571Q31024172-A09F411B-E836-4E2E-9295-6A3733356D4CQ33470615-86C3F902-5591-424D-892A-C6A8DFA52DE9Q34546774-D897CB01-0644-4372-AF2B-EBA5E962A9C4Q34582022-D981CF5C-2CEA-4E1C-BC25-6158FE7E7B77Q35584746-285AEF65-2B8A-4197-A723-A13F66F285B9Q37598267-4BAD7D2C-C05E-49C1-9F59-A08C60636A9CQ37783616-C85096A2-84D7-4594-80FA-5AD28287FE6AQ37800110-31F58CA4-0544-4C25-8B3B-69240A56721FQ37832931-F0476DF0-09CD-404A-89BB-D305FC80EBB6Q37875004-1FF47B48-F38C-4168-8B7B-F503F88EBF91Q37983692-6B938BF7-A1AB-4C09-A589-3504D8906769Q38007857-0562DB43-0E3F-406D-9F17-DBF1D3D0A5CEQ38264533-BE7EFB49-4014-4065-BBB0-A53D030EA6D2Q38585273-16943FDE-F811-48DC-A033-8C7234059C20Q38881452-0569D59C-5823-43D1-9C15-7798838283F6Q39636226-C47983F5-F106-4363-8BF1-50C167285A8AQ39657289-FB688177-F39B-47B0-9F55-665BA82B06D3Q43213667-F85D86F8-2F42-42B8-A2BC-E42973C2BD6FQ51617622-4FD184C7-BD98-4F8A-A963-C03EFF69F570
P2860
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Phase I clinical evaluation of ...... in patients with solid tumors.
@ast
Phase I clinical evaluation of ...... in patients with solid tumors.
@en
Phase I clinical evaluation of ...... in patients with solid tumors.
@nl
type
label
Phase I clinical evaluation of ...... in patients with solid tumors.
@ast
Phase I clinical evaluation of ...... in patients with solid tumors.
@en
Phase I clinical evaluation of ...... in patients with solid tumors.
@nl
prefLabel
Phase I clinical evaluation of ...... in patients with solid tumors.
@ast
Phase I clinical evaluation of ...... in patients with solid tumors.
@en
Phase I clinical evaluation of ...... in patients with solid tumors.
@nl
P2093
P1476
Phase I clinical evaluation of ...... in patients with solid tumors.
@en
P2093
Alan J Barge
Antoinette Wozniak
Catherine Wheeler
Helen K Jones
Jeffrey L Evelhoch
Pamela A DeLuca
Patricia M LoRusso
Scott A Boerner
Shirish M Gadgeel
Zachary S DelProposto
P2860
P2888
P304
P356
10.1007/S10637-008-9112-9
P577
2008-01-25T00:00:00Z
P6179
1029579791